SMARCA4 and cancer: Our data show that SMARCA4/2-deficient cancer cells are resistant to cisplatin in part through suppression of IP3R3 and that ectopic IP3R3 expression can sensitize these cancer cells to cisplatin-induced apoptosis (Fig. 4g–k, Supplementary Fig. 10).